The SLBT SEC filings page on Stock Titan is intended to provide access to regulatory documents associated with SL Science Holding Limited, the post-business combination holding company tied to SL BIO Ltd. and Horizon Space Acquisition II Corp. SLBT is expected to be the Nasdaq ticker symbol for this holding company if the proposed business combination is completed and listing conditions are met.
For this transaction, a registration statement on Form F-4 has been declared effective by the U.S. Securities and Exchange Commission. That document, together with the accompanying proxy statement/prospectus, describes the terms of the business combination between SL BIO Ltd., a biomedical company focused on cellular and gene therapies, and Horizon Space Acquisition II Corp., a special purpose acquisition company (SPAC). Once available under the SLBT symbol, SEC filings can include registration statements, periodic reports, and other disclosures relating to the combined company.
Stock Titan enhances these filings with AI-powered summaries that are designed to highlight key sections of lengthy documents. For example, when SLBT files annual reports on Form 10-K or foreign private issuer equivalents, quarterly reports on Form 10-Q (if applicable), or current reports on Form 8-K, the platform can surface major risk factors, business descriptions, and transaction updates in a more accessible format.
In addition, when insider transaction reports on Form 4 or other ownership-related filings become available for SLBT, this page will organize them alongside other SEC submissions. Real-time updates from the EDGAR system and AI-assisted explanations help users quickly understand the regulatory information that shapes the SLBT investment profile.
SL Science Holding Ltd reported that Dr. Ethan Shen resigned as a director and Chief Technology Officer effective November 1, 2026. He is no longer subject to Section 16 reporting.
SL Science Holding Ltd (SLBT) announced that Dr. Ethan Shen resigned as a director and Chief Technology Officer effective November 1, 2026. The board accepted his resignation, which the company said was not due to any disagreement over its operations, policies or practices. On the same date, the board appointed Dr. Chin-Sheng Hung as a director and Chief Medical Officer.
Dr. Hung has experience in surgery, physician training and education, and hospital administration. Since July 2025, he has served as Director of the Medical Administration Department at Taipei Medical University Hospital; before that, he was Chief of Surgery there from July 2021 to July 2025.
SL Science Holding Limited (SLBT) reported revenue of $1,386,608 for the six months ended June 30, 2026, compared with $1,129,238 a year earlier; revenue consisted of exosome concentrate sales. Gross profit was $557,484 versus $389,066. Operating expenses rose to $2,719,661 from $1,998,808, and net loss increased to $2,162,205 from $1,602,089. Net cash used in operating activities was $2,091,682, compared with $134,157.
At June 30, cash and cash equivalents were $8,306,692 and working capital was approximately $6.7 million. Management said it plans profitability improvements and debt financing and loans from existing shareholders; it believes the financing could fund obligations for at least 12 months from the statement date. The June 12 business combination included PIPE financing of 780,000 units at $10.00 each for $7,800,000 in gross proceeds. As of June 30, the CD-19 Armed-T and GDT therapy candidates had not received FDA clearance or approval, completed Phase I, II or III clinical trials, or had an IND application submitted. A further $37 million under the GDT license is payable when specified conditions and milestones are met.
SL Science Holding Ltd. (SLBT) reports that SL Link Co., Ltd. sold and transferred 4,545,306 ordinary shares to Ching-Dong Wang on September 29, 2026, for an aggregate purchase price of US$2,272,653. Wang, the company’s Chief Executive Officer, director, and Chairman of the Board, continued to beneficially own 333,832,129 shares after the transfer.
That total includes 329,286,823 shares held by SL Link Holding Ltd. and 4,545,306 held by Wang. The reported ownership is approximately 59.53%, based on approximately 560,759,740 ordinary shares issued and outstanding; the calculation excludes 260,000 ordinary shares convertible on December 12, 2026, from 780,000 preferred shares outstanding as of October 1, 2026.
SL Science Holding Ltd (SLBT) Chief Executive Officer Ching-Dong Wang purchased 4,545,306 ordinary shares from SL Link Co., Ltd. on September 29, 2026, for an aggregate purchase price of US$2,272,653. The transaction’s reported per-share price is not usable. After the transfer, Wang beneficially owned 333,832,129 ordinary shares, unchanged in total: 329,286,823 were held by SL Link Holding Ltd and 4,545,306 were held directly by Wang. No Rule 10b5-1 plan is reported.
SL Science Holding Ltd elected the Cayman Islands home-country practice exemption from eight Nasdaq Marketplace Rule 5600 Series requirements. The exceptions cover a majority-independent board and meetings attended only by independent directors; annual shareholder meetings no later than one year after fiscal year-end; proxy solicitation and providing proxy materials to Nasdaq; and shareholder approval for specified acquisition, change-of-control, equity-compensation and certain non-public securities issuances, including issuances of 20% or more of outstanding voting power below the defined minimum price. Cayman Islands counsel Ogier stated that Cayman law and the company’s current memorandum and articles do not prohibit these practices and do not require compliance with the listed requirements, except where required by Nasdaq, the SEC or another competition regulatory authority. Ogier’s opinion is limited to Cayman Islands law. The company stated that, apart from these exceptions, its governance practices do not significantly differ from those of U.S. domestic companies under Nasdaq listing standards.
SL Science Holding Ltd (SLBT) filed a Form 4 indicating that Mr. Johnson Lau (Lau Johnson Shun-Pong) resigned as Vice President of Finance effective August 31, 2026. The filing reports no insider transactions, and notes that he is no longer subject to Section 16 reporting requirements.
SL Science Holding Ltd (SLBT) reported a management change. On August 24, 2026, Johnson Lau submitted his resignation as Vice President of Finance to the board of directors. The board accepted his resignation, which is effective August 31, 2026. The company states that Mr. Lau’s resignation was not due to any disagreement regarding its operations, policies, or practices.
SL Science Holding Ltd (SLBT) reported a change in its independent auditor. On August 21, 2026, the company appointed TAAD LLP as its independent registered public accounting firm, effective the same day, replacing ARK Pro CPA & Co, which was dismissed on August 20, 2026. The change was approved by the audit committee after a consideration and evaluation process, and the company states it was not due to any disagreements with ARK over accounting principles, financial statement disclosures, or audit scope or procedures, and that there were no “reportable events” as defined in Item 16F of Form 20-F.
ARK’s prior audit reports on the consolidated financial statements of SL BIO Ltd. for 2024 and 2025 contained no adverse or qualified opinions. ARK’s report on SL Science Holding Ltd’s consolidated financial statements as of December 31, 2025 (from inception on March 18, 2025) likewise contained no adverse or qualified opinions, but did include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern. The company states it did not consult TAAD on accounting or audit matters before TAAD’s engagement. ARK has been asked to provide a letter to the SEC agreeing or disagreeing with these disclosures, which is filed as an exhibit.